NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM).

NXT629 is a potent and selective antagonist of PPAR-α(human PPARα,IC50 of 77 nM), shows high selectivity over other nuclear hormone receptor, [2].

NXT629 has poor oral bioavailability in mice and rats.?NXT629 (30 mg/kg, i.p., daily for 6 weeks) delays growth of subcutaneous SKOV-3 tumors in nude mice, inhibits growth of subcutaneous B16F10 tumors in C57Bl/6 mice.?NXT629 (30 mg/kg, i.p.) is weakly anti-angiogenic against FGF-induced angiogenesis.?NXT629 (3, 30 mg/kg, i.p.) inhibits experimental metastasis of B16F10 melanoma cells to the mouse lung[2].

1454925-59-7

C35H39N5O3S

609.78

DMSO:125 mg/mL (204.99 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years